Globe Newswire12.27.18
BioSig Technologies Inc., a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, has entered into a new advanced research agreement with Mayo Clinic in Rochester, Minn.
The new program will be run under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s vice-chair of Innovation and medical director of the Electrophysiology Laboratory. The program will consist of a number of two-to three-year projects, which will focus on development of additional advanced features of PURE EP System within the field of electrophysiology and potential clinical applications of BioSig’s technology in a new, previously unexplored, field.
“We are very pleased to continue our collaboration with Dr. Asirvatham and the team at Mayo Clinic. Our pre-clinical studies have shown the strong potential of PURE EP System to improve clarity of cardiac signals during the ablation procedures and related studies. We are confident that enhanced product development of our PURE EP System and testing of its advanced features at the number one hospital in the nation will lead to increased value proposition of our technology. We are fully committed to deliver outstanding value to our shareholders and our future clients,” commented Kenneth L. Londoner, chairman and CEO of BioSig Technologies Inc.
BioSig received U.S. Food and Drug Administration 510(k) clearance for the PURE EP System on Aug. 8. The company began trading on the Nasdaq Capital Market on Sept. 21 under the ticker symbol BSGM. The company completed 12 pre-clinical studies at Mayo Clinic to date and has signed a 10-year collaboration agreement with the Clinic in March 2017.
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. Los Angeles, Calif.-based BioSig Technologies is preparing to commercialize its PURE EP System. The technology has been developed to address an unmet need in a large and growing market.
The company’s first product, PURE EP System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision- making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, atrial fibrillation and ventricular Ttachycardia. BioSig has partnered with Minnetronix on technology development.
The new program will be run under the leadership of Samuel J. Asirvatham, M.D., Mayo Clinic’s vice-chair of Innovation and medical director of the Electrophysiology Laboratory. The program will consist of a number of two-to three-year projects, which will focus on development of additional advanced features of PURE EP System within the field of electrophysiology and potential clinical applications of BioSig’s technology in a new, previously unexplored, field.
“We are very pleased to continue our collaboration with Dr. Asirvatham and the team at Mayo Clinic. Our pre-clinical studies have shown the strong potential of PURE EP System to improve clarity of cardiac signals during the ablation procedures and related studies. We are confident that enhanced product development of our PURE EP System and testing of its advanced features at the number one hospital in the nation will lead to increased value proposition of our technology. We are fully committed to deliver outstanding value to our shareholders and our future clients,” commented Kenneth L. Londoner, chairman and CEO of BioSig Technologies Inc.
BioSig received U.S. Food and Drug Administration 510(k) clearance for the PURE EP System on Aug. 8. The company began trading on the Nasdaq Capital Market on Sept. 21 under the ticker symbol BSGM. The company completed 12 pre-clinical studies at Mayo Clinic to date and has signed a 10-year collaboration agreement with the Clinic in March 2017.
BioSig Technologies is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. Los Angeles, Calif.-based BioSig Technologies is preparing to commercialize its PURE EP System. The technology has been developed to address an unmet need in a large and growing market.
The company’s first product, PURE EP System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision- making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, atrial fibrillation and ventricular Ttachycardia. BioSig has partnered with Minnetronix on technology development.
